Fundz

Neurosoft Bioelectronics raises $7.5M in an oversubscribed Seed round led by Skybound Venture Capital to develop advanced brain-computer interfaces.

PRIVATEMay 20, 2026

Amount Raised

$7.5 Million

Round Type

Seed

New YorkBiotechnologyHealth CareMedical DeviceHealth Diagnostics

Investors

PL CapitalIAG Capital PartnersConnecticut InnovationsSkybound Venture Capital

Description

Neurosoft Bioelectronics has secured a $7.5 million oversubscribed seed financing round to enhance its minimally invasive brain interface platform. The company, headquartered in Switzerland with a presence in New York, aims to accelerate the development of its AI-powered neurotechnology. With this funding, Neurosoft's total raised exceeds $20 million, showcasing strong investor confidence. The round's participants include PL Capital, IAG Capital Partners, and Connecticut Innovations.

Who else raised in Medical Device and Health Diagnostics around the same time

Companies in the same sectors as Neurosoft Bioelectronics that raised within 45 days of this round, from Fundz verified event records.

  • Grail raised $110M (Post-IPO Equity) on June 25, 2026.
  • Imagion Biosystems raised $2.8M (Post-IPO Equity) on June 25, 2026.
  • Uncovr raised $7M (Seed) on June 10, 2026.
  • Captive Radiology raised an undisclosed amount on May 27, 2026.
  • ClearNote Health raised $52M (Series D) on May 27, 2026.
  • Vortex Imaging raised $12M (Funding Round) on May 18, 2026.

Who to call at Neurosoft Bioelectronics, and when

A new round usually means Neurosoft Bioelectronics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Neurosoft Bioelectronics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Neurosoft Bioelectronics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Neurosoft Bioelectronics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Neurosoft Bioelectronics

Location

New York, United States

About

Neurosoft Bioelectronics is a neurotechnology company developing scalable and soft brain-computer interfaces (BCIs). The company focuses on creating minimally invasive brain interface platforms and is advancing clinical trials in the United States and Europe. With a proprietary soft, stretchable electrode technology, Neurosoft enables access to the full cortex without penetrating brain tissue. They aim to leverage neural data for significant advancements in both invasive and non-invasive BCIs.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Neurosoft Bioelectronics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Neurosoft Bioelectronics's next move

See what Strategic adds

Neurosoft Bioelectronics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.